Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 270 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MVjGeY5kfGmxbjDBd5NigQ>? NYCwXIVlOC55zszN MYmyOIg> MUjleIhidm:u NWTmOphx\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= MnLPNlU4QDdyN{m=
TE13 Mn3jSpVv[3Srb36gRZN{[Xl? NFHYOXMxNjQQvF2= NFr4d44zPGh? NYfNS4RbfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> NEDOcpUzPTV5OU[2OS=>
TE13 MUDBdI9xfG:|aYOgRZN{[Xl? Ml61NE4{|ryP MonDNlRp M{\Fc4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MkHsNlU2Pzl4NkW=
MEFs NHv4fZpHfW6ldHnvckBCe3OjeR?= NGf0VGo2|ryP NEi1SZgyPmh? NVzMcVlPcW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w NUnWUWs4OjV2OEK2N|Q>
SW480  MYLGeY5kfGmxbjDBd5NigQ>? M3;KXFAvOc7:TR?= M134elQ5cA>? NWDUPHBjTE2VTx?= MmjndoV3\XK|ZYOgSW1V MnnoNlU1OzR7OUe=
PC3  MVfGeY5kfGmxbjDBd5NigQ>? NWfLT5FjOC5zzszN M2PyPVQ5cA>? NV;GSJlwTE2VTx?= M4rNUJJmfmW{c3XzJGVOXA>? M3rqOFI2PDN2OUm3
SW480  MX7GeY5kfGmxbjDBd5NigQ>? NGTnSXUxNjIQvF2= NYLIdpBuPDiq MXLEUXNQ NIG4OHpifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NFfxS3IzPTR|NEm5Oy=>
PC3  M2PmN2Z2dmO2aX;uJGF{e2G7 NVTOepN3OC5zzszN M2rwSlQ5cA>? NUf4R41FTE2VTx?= Mn7uZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w NHO1O|IzPTR|NEm5Oy=>
SW480  M1\3SWZ2dmO2aX;uJGF{e2G7 NHjaSmcxNjIQvF2= M2\kZVQ5cA>? NWPBUpJwTE2VTx?= MX7pcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MmHBNlU1OzR7OUe=
PC3  MXHGeY5kfGmxbjDBd5NigQ>? NEj3XZIxNjIQvF2= MYS0PIg> M3WyZmROW09? NX3yd3gzcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NXjNW3R6OjV2M{S5PVc>
A431 M1\NXGFxd3C2b4Ppd{BCe3OjeR?= M2OxXFIwOTBxNUCvNVAxdk1? MlvsOFhp NEnNZ4JFVVOR MnL5bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq MUKyOVM4OTB4OR?=
A431 NFvNNlZHfW6ldHnvckBCe3OjeR?= NFvvb2U2OG6P NFO2WoozNzZxMUKvNlRp NWT0dYNVTE2VTx?= M{S3O4FkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= M1GwW|I2OzdzME[5
MDA-MB-231 NULte|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;hTmR4OC14MEDuUS=> MoTjNlRp M4n1VmROW09? NEDRNWlKSzVyIH;mJFExOG6P M4r5TVI2OTl{N{Kx
MCF7 NYLGdGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjYTmFIOC14MEDuUS=> MlvGNlRp NUDUb2YyTE2VTx?= MXHJR|UxKG:oIEe1cm0> M4TEVlI2OTl{N{Kx
SKOV-3 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HnS|EuOTEQvF2= MkS4NlRp NVS5XJVnTE2VTx?= MYLJR|UxKG:oIEWuOu69VQ>? MXKyOVE3QTR7MR?=
A549 NFrXO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxMVEx|ryP MWKyOIg> MVzEUXNQ NY\HW2w4UUN3MDDv[kA{NjMQvF2= M361fVI2OTZ7NEmx
SKOV-3 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rkOFAvOS1zzszN NH3vN5E1QGh? MkS3SG1UVw>? NV34UlN4UUN3MDDv[kAxNjgQvF2= NHHSOnEzPTF4OUS5NS=>
A549 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rUZVAvOS1zzszN MVm0PIg> MX7EUXNQ MmLxTWM2OCCxZjCwMlI5|ryP M3LHWVI2OTZ7NEmx
SKOV-3 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL2S5cxNjBzLUCuPe69VQ>? M3HZW|czcA>? NEXzNlRFVVOR NX7MeGlpUUN3MDDv[kAxNjN{zszN MXeyOVE3QTR7MR?=
A549 NHLQb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7ONE4xOS1yLkpOwG0> M2\CeFczcA>? NFfqdplFVVOR NWfJU2FbUUN3MDDv[kAxNjB4zszN NF7UU5UzPTF4OUS5NS=>
HeLa MkjnSpVv[3Srb36gRZN{[Xl? MV6yOVBvVQ>? Mon5NVZp MkPUSG1UVw>? M2\EZYlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= NVjuNo9ZOjVzMU[2PFg>
CNE2 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLycoZkOTByLU[wNI5O NUDLSHV7OjRxNEivO|Jp M1jBbYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX2yOFk3QTlyMR?=
PC3 NXzpUGVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPxNVAxNTFyMEDuUS=> M3X0[VI1cA>? MYjJR|UxKG:oIEOwNI5O NY\JcmZzOjR6NUS2OVg>
LNCaP NVzac3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixNFAuOTByMH7N Mo\vNlRp M4Oze2lEPTBib3[gN|Axdk1? MVqyOFg2PDZ3OB?=
HeLa  NGi2fGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne2Nu69VQ>? NUe1eIZPPDiq NWTnbXIz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> MoCyNlQ5PDZzM{W=
HMEC-1  NWK1bIpWTnWwY4Tpc44hSXO|YYm= MlPXN|Axdk1? M2GwT|I1cA>? NWX5fWF5cW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? Mn73NlQ4OTB4M{G=
HeLa NGf4OolHfW6ldHnvckBCe3OjeR?= M2r2b|FuVQ>? NE\6cHkxNjWq Moj3ZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 MlfVNlQ4ODd2N{S=
ACP02 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfqTnNsOjVyL{O1NE82ODCwTR?= NETOXnQzPGh? MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O NHO1fYozPDZ4OEW0Oy=>
ACP03 M1XNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Ht[|I2OC9|NUCvOVAxdk1? MoHPNlRp M2PmVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MX2yOFY3QDV2Nx?=
U87 GBM NFviOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xNFAwOzByL{WwNEBvVQ>? MlLZO|IhcA>? MXGxNFAmKGW2aHHuc4w> M3j1VJJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> NFrKcm8zPDR4NEi0NS=>
U87 GBM M{P3bWZ2dmO2aX;uJGF{e2G7 NF\3dFIyODBxNUCwJG5u MUe0PEBp M3fmR|ExOCViZYToZY5wdA>? NYDNbWYzUW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7 MWGyOFQ3PDh2MR?=
RPE MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\5VVAvOi9yLkSvNE45NzFizszN M171fVI1NzR6L{eyJIg> M1rnOGROW09? NIn5d5dqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MV2yOFQ2PjZyMh?=
HT29  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxPFAhdk1? NVjUeWJyPzJiaB?= M3v3bmlEPTBib3[gNVgxKG6P MWGyOFM3QDJ4NR?=
hMSCs MVrGeY5kfGmxbjDBd5NigQ>? M{LOfVYvOjVibl2= M33zNFI1KGh? NFLTbHFFVVOR NXO4PGVXe3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> NH[0NWkzPDNzMkO1Oi=>
Huh7  MoOxSpVv[3Srb36gRZN{[Xl? NYTR[oxqOC5zL{CuOU8yNjBizszN M{jGW|I1cA>? NITlbIh{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= MWCyOFI3QTZ5Mh?=
SKOV3 NX21eHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHtNE4xPS1{IN88US=> M3nZNVExNzJ2L{S4JIg> M{HF[WROW09? MUXt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M4WwS|I1OjJ|OECx
A2780 M2njTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XhN|AvODVvMjFOwG0> NYi3XJZKOTBxMkSvOFghcA>? MnXPSG1UVw>? NXfhb4NVdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NVLheoNrOjR{MkO4NFE>
SRA01/04  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELS[VAxNjJizszN M{\C[|Q5KGh? M2TROGROW09? MojGd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NHLDd4szPDF3N{i3PC=>
HLEB3 NGL3WHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37tZ|AvOiEQvF2= MkDuOFghcA>? MVzEUXNQ MofGd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> M1\OR|I1OTV5OEe4
SRA01/04  NXTEWGhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzUWkxNjRxMD64JO69VQ>? NUfLVFBFPDhiaB?= MoroSG1UVw>? NG\COGdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1Lr[FI1OTV5OEe4
HLEB3 NHrxPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HBWFAvPC9yLkig{txO MVG0PEBp NHjBV4ZFVVOR MnvObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MV2yOFE2Pzh5OB?=
HCT116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCwMlIh|ryP NX:4OWFrOTJiaB?= MnfP[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= M{\neVI1OTJ{MkOx
CA46 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGzM|YwOTJxMkSvOFghdk1? Mlv6OFghcA>? M2fSWYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NFHMN44zPDB4NEm1NS=>
PMNs NVHHXncyTnWwY4Tpc44hSXO|YYm= MYGzNEBvVQ>? MkD1OFghcA>? Mo[ybY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 NXe1flNVOjN7OEi2NVc>
H1299 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS2N4JQOcLizszNxsA> MXmyOE81QC95MjDo MV7leIhidm:u MYXpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> M3fXW|I{QTF4NkC5
A549 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hjc|AvOjVxMD61M|Eh|ryP MXuyOE81QC95MjDo NX3iR28{\XSqYX7vcC=> MnrUbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MkXKNlM5Pjd7OUG=
H1299 NFqwSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHncplQOC5{NT:wMlUwOSEQvF2= M2rRb|I1NzR6L{eyJIg> MYDleIhidm:u M{i0UYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MXSyN|g3Pzl7MR?=
A549 M{HpcmFxd3C2b4Ppd{BCe3OjeR?= Ml21NE42NzFizszN M1nLfFQ5KGh? MYLleIhidm:u M3HSNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXyyN|g3Pzl7MR?=
H1299 MWDBdI9xfG:|aYOgRZN{[Xl? MkC1NE42NzFizszN M2\S[|Q5KGh? MYPleIhidm:u NGXKOoRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2Hhb|I{QDZ5OUmx
SUM149PT M2jFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XRVlIwPy53L{GwJO69VQ>? MlryOFghcA>? M4LNU2ROW09? MoTFbY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? MkOxNlM4QTJ4M{i=
SUM190PT M1Lpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi1Ono2OC9zMECvNlUxKG6P Ml[4OFghcA>? MWXEUXNQ NHXhUYRqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? MYGyN|c6OjZ|OB?=
HCT1 NFLZSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS1T3luOC5{L{GuNE82NjBizszN NUP5OIdEOTJxMkSvN|YwPDhiaB?= M2TFcIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NVzw[|Q1OjN5N{CwNFA>
Lovo Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMlIwOS5yL{WuNEDPxE1? M2fBS|EzNzJ2L{O2M|Q5KGh? M162[Ylv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M{\UUVI{PzdyMECw
AGS NHHqV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnJS|M{OC5yMUWtNUDPxE1? MU[3NkBp MUfpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= MUSyN|c1PTB{NB?=
Huh7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7oNUDPxE1? MXqyOEBp NYjlWHhlTE2VTx?= MWPy[YR2[2W|IHHic5V1KDJyJTD2bYFjcWyrdIpCpC=> NIDMUZQzOzZ2M{mzNy=>
ECC1 M1Xp[2Z2dmO2aX;uJGF{e2G7 NVfJSVZpPTByIH7N NGX3TZE2KGR? MkjxSG1UVw>? MVHpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NUHWflhpOjN3M{C3Olk>
HEC1A MW\GeY5kfGmxbjDBd5NigQ>? MkHLOVAxKG6P NVrqcIZyPSCm MWPEUXNQ NILncpVqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NGPKOVIzOzV|MEe2PS=>
EN1 MUTGeY5kfGmxbjDBd5NigQ>? M4OwUlUxOCCwTR?= MVW1JIQ> M3;CO2ROW09? M{\OZolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NF;lZoIzOzV|MEe2PS=>
MFE296 NYfrR2s6TnWwY4Tpc44hSXO|YYm= NWHpNZg4PTByIH7N MVu1JIQ> NEfkZmNFVVOR MlHVbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MlW3NlM2OzB5Nkm=
HASMCs MV3GeY5kfGmxbjDBd5NigQ>? MkLVNE02ODBibl2= MVu2JIQ> NXr2[GVW\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? MkWxNlM2OTh2Nke=
U373 NHjoblZHfW6ldHnvckBCe3OjeR?= Mn3ENE4zPS9yLkWvNUDPxE1? NEHzc3EzPCCq Mln3bY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? NIO3bmgzOzR5NEG3NS=>
ARN8  NX3lcldwTnWwY4Tpc44hSXO|YYm= MlXBNE4xPS1{IN88US=> MniyNlQhcA>? MWjy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NGHVSWIzOzR5MEW0NC=>
MCF7 NYjTVGFvTnWwY4Tpc44hSXO|YYm= NHjtcYwxNjB3LUKg{txO NE[4SI4zPCCq MonsdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NFzTOVIzOzR5MEW0NC=>
H1299  M4LGVGZ2dmO2aX;uJGF{e2G7 MUGwMlM{6oDVMdMgxtVO MkLSNlQwPDhiaB?= M3LBSGROW09? NHTBNmxqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 NFS2ZYgzOzR4MUm3OS=>
H1299 NX3GNI93TnWwY4Tpc44hSXO|YYm= M1nrOlAvPSEQvF2= M4KzVVQ5KGh? MnSwSG1UVw>? NXf2XFI1cW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? M{nKOlI{PDZzOUe1
H1299 M32wNWZ2dmO2aX;uJGF{e2G7 MnTKNE42KM7:TR?= M1Xu[|Q5KGh? NUnlfHBiTE2VTx?= Mm\HbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? MoCwNlM1PjF7N{W=
MG-63  Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLKNE4{KM7:TR?= NEHPNGgyOi17NjDo NFLWb3dFVVOR NXy0[XZEcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NH3DfGozOzR3MUixOy=>
LM8 NEXiVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rmWVAvOyEQvF2= NFjPXFYyOi17NjDo M4DiPGROW09? NE\1OHJqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NV:x[IhkOjN2NUG4NVc>
K562 M13wT2Z2dmO2aX;uJGF{e2G7 NV;5N|F1OC53IN88US=> MnnKNlQhcA>? MYfleIhidm:u NH3wfZFl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NFXsUo8zOzR|MEm1Oy=>
HEL NGfnNGNHfW6ldHnvckBCe3OjeR?= MUWwMlUh|ryP M1rI[VI1KGh? M{nnZoV1cGGwb3y= NInhdotl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? MmO2NlM1OzB7NUe=
HL60 MmC0RZBweHSxc3nzJGF{e2G7 NETSU2IyKM7:TR?= NUnGNoFbOjRiaB?= MX\pcoR2[2W|wrDj[YxtKGSnYYTo NGHBdXAzOzRyMEWxPS=>
KG1 NHPCdYtCeG:ydH;zbZMhSXO|YYm= M{T0flEh|ryP MVyyOEBp NY\XZldYcW6mdXPld:Kh[2WubDDk[YF1cA>? MmHWNlM1ODB3MUm=
Kazumi NXzmW4NDSXCxcITvd4l{KEG|c3H5 MoCwNUDPxE1? NHvM[mwzPCCq MV\pcoR2[2W|wrDj[YxtKGSnYYTo NFvr[2ozOzRyMEWxPS=>
K562 MWLBdI9xfG:|aYOgRZN{[Xl? M1qzT|Eh|ryP MWCyOEBp MU\pcoR2[2W|wrDj[YxtKGSnYYTo NEm3OoYzOzRyMEWxPS=>
THP1 MmfZRZBweHSxc3nzJGF{e2G7 NIXQcHEyKM7:TR?= NXf6WnVuOjRiaB?= NInSXVdqdmS3Y3XzxsBk\WyuIHTlZZRp M3vjR|I{PDByNUG5
SH-SY5Y MknYSpVv[3Srb36gRZN{[Xl? MnrDNlUxKG6P MlHoNVYhcA>? NEPpboFkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 M1P1OlI{OzJ4NEKy
HEK293 MlqySpVv[3Srb36gRZN{[Xl? MVexJOK2VcLi MnTmNVghcMLi NFXMfpRqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| MVWyN|I5PDh2OB?=
HTK MVPGeY5kfGmxbjDBd5NigQ>? MmLoOFAxKG6P MWi3NkBp M4[3W4lvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> M2XoNlI{Ojh2MECy
HTK Mn7HSpVv[3Srb36gRZN{[Xl? MWOxNFAuQDBybl2= MnnjO|IhcA>? NWWzN5d1[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= MY[yN|I5PDByMh?=
Caco-2  NX3ETlI4TnWwY4Tpc44hSXO|YYm= M3HqXFEhyrWPwrC= MXqyOEBp NV2y[HVX\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u MnTiNlMyQTVyN{C=
HeLa MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X4[|ExOCCwTR?= MmK3NlQhcA>? NWGwT2dPTE2VTx?= MmnOTWM2OCCxZjCxNFBvVQ>? NYT1V4tPOjNzNkW3OFg>
HeLa M{H2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnUSXl4PDBibl2= NH;k[Xo1QCCq MUjEUXNQ Mk\6TWM2OCCxZjC0NI5O NXPiPGtNOjNzNkW3OFg>
HeLa NXTX[XNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DtNlIxKG6P NVPnU2RQPzJiaB?= Mki5SG1UVw>? MV3JR|UxKG:oIEKwcm0> NHKzSXczOzF4NUe0PC=>
HeLa MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCxWlYyOC9|MD:1NEBvVQ>? NX;SXZBbPzJiaB?= M2HUNWROW09? NX\DZnBvcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 NUXtd|hGOjNzNkW3OFg>
MDA-MB-231 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\sNVI2NTRyMDDuUS=> Mk\yOFghcA>? MkGzTWM2OCCxZjCyOlMvOm6PwrC= MlrUNlMxPTVzOUi=
MCF-7  NFfUb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXPXozPS12MECgcm0> Mln4OFghcA>? MnnFTWM2OCCxZjCyNlAvPG6P Mk\qNlMxPTVzOUi=
ECC-1  M1H6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj3UHMyODBibl2= MVOyOEBp NGLpTY1mfGijbn;s MkWzbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn NVXyOHdlOjNyMki4NFM>
HEC-1A NHzMcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHPXZgyODBibl2= NEHLOmczPCCq NWLwVmU{\XSqYX7vcC=> NFTQflZqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= Mmn5NlMxOjh6MEO=
NHAC-kn M3rIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNE8yODBxNUCwJI5O NUO5SJRzOTJiaB?= NVrKN2s2TE2VTx?= NGX6eIhKSzVyIH;mJFUxOG6P NW\UXo5lOjNyMUe4O|E>
A549 NU\uUXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHflbVUzPTBibl2= MkT4Ok04OiCq MVHEUXNQ NH;zOZFk[XW|ZYOgZUBoemWjdHXyJIlvcGmkaYTvdpkh\W[oZXP0JINwdWKrbnWge4l1cCCWWGSgc5Ih\XKub4Tpcolj M1;Qd|IzQTl2N{iw
MG-63 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLsfY15OzByIH7N MYWxNkBp NXXzWYpvTE2VTx?= NInVU4RqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn NGnxdnczOjd7OUOzPC=>
MG-63 NIfyRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\aeGQ{ODBibl2= MUCyOEBp MVrEUXNQ MXfpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm NGfzT4UzOjd7OUOzPC=>
MG-63 NEWzW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKzNFAhdk1? NXGwSllVPDhiaB?= MnLjSG1UVw>? NHXL[4pqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn M{TFZlIzPzl7M{O4
HL60  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixOVAuOzVyIH7N NIHkZVUzPCCq NUjxbYNRcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NE[xeHUzOjd3M{ezPS=>
U937 NFnFSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4UJpzOTVyLUO1NEBvVQ>? NIfKS3IzPCCq MXLpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N NIKxbYIzOjd3M{ezPS=>
SCC-6 NHLIOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCyNFAuOzJyMDDuUS=> M37t[|EzNzJ2L{S4JIg> MUPEUXNQ NEnKXoZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M1;US|IzPTV{M{Kx
U87  NV;vfHN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrnU21YOTByLUOwNEBv\w>? NV;icYpLOjRiaB?= NVuyRldGcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= NVzwZoZLOjJ{N{C4OFk>
K562 MnrhSpVv[3Srb36gRZN{[Xl? NILRTIMyKM7:TR?= M3\neVEzKGh? NHTRSWZFVVOR NXj3NpA3\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NFjrcVMzOjF5OUG5PC=>
Reh MnXKSpVv[3Srb36gRZN{[Xl? MYCwMlMwOSEQvF2= M1\Pc|EzKGh? MlK0SG1UVw>? NIq0WWpmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> M4fXUFIzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay
+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research
+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Active, not recruiting Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --
NCT02754024 Active, not recruiting Idiopathic Osteoarthritis|Posttraumatic Osteoarthritis|Humeral Head Necrosis|Instability Arthritis Werner Anderl|Austrian Research Group for Regenerative and Orthopedic Medicine September 2005 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID